Evidence map›Paper›PMID 39976806›Full record

ArticleInfection2025

Oral nonabsorbable antibiotics for prevention of recurrent cholangitis; a brief report study.

Jesús Fortún, Miguel Angel Rodríguez-Gandía, Vicente Pintado, Pilar Martín-Dávila, Miguel García-González, Javier Graus, Rosa Martín-Mateos, Javier Saez de la Fuente, Alfonso Muriel, Santiago Moreno

Registry-linked trialAbstract read
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07509346 (Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation Versus Standard Treatment in Patients With Recurrent Non-Obstructive Acute Cholangitis - COLANBIOTA Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07509346 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation Versus Standard Treatment in Patients With Recurrent Non-Obstructive Acute Cholangitis - COLANBIOTA Trial

TypeinterventionalSponsorPuerta de Hierro University HospitalRan2026 to 2029Enrolled44ConditionsCholangitis Acute, RecurrenceArmsFecal Microbial Transplantation
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jesús FortúnDepartment of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, Madrid, 28034, Spain. fortunabete@gmail.com.
Miguel Angel Rodríguez-GandíaInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Vicente PintadoDepartment of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, Madrid, 28034, Spain.
Pilar Martín-DávilaDepartment of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, Madrid, 28034, Spain.
Miguel García-GonzálezInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Javier GrausInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Rosa Martín-MateosInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Javier Saez de la FuenteInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Alfonso MurielInstituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), Madrid, 28034, Spain.
Santiago MorenoDepartment of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, Madrid, 28034, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with recurrent cholangitis are at risk of developing life-threatening sepsis. Selective decontamination of the digestive tract (SDD) involving oral nonabsorbable antibiotics has been primarily applied to children undergoing Kasai portoenterostomy surgery.

methodsIn this study, SDD containing colistin, tobramycin, and nystatin was administered to eight patients with recurrent cholangitis, and the incidence density before and after SDD administration was analyzed.

resultsThe overall incidence density of cholangitis requiring hospital admission was 0.37 per 100 patient days during the SDD period and was significantly lower than observed before SDD administration (1.05 per 100 patient days) [RR: 0.35 (95% CI: 0.21-0.59); p: <0.001, two-sided]. This was not associated with an increased risk of resistance during SDD administration.

conclusionIn this study SDD reduced by 65% the frequency and severity of recurrent cholangitis. In addition, this procedure is patient-friendly and microbiologically safe.

Indexed as

Anti-Bacterial AgentsCholangitisSecondary PreventionAdministration, OralAdultAgedAged, 80 and overColistinDrug CombinationsFemaleGastrointestinal AbsorptionGastrointestinal TractHumansMaleMiddle AgedNystatinAnti-Bacterial AgentsColistinDrug CombinationsNystatinTobramycinOral nonabsorbable antibioticsPreventionRecurrent cholangitisSelective decontamination of the digestive tract

Identifiers

PMID39976806
PMCPMC12137420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.